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In the present study, a 50% ethanolic extract of Orthosiphon stamineus was tested for its 𝛼-glucosidase inhibitory activity. In vivo
assays of the extract (containing 1.02%, 3.76%, and 3.03% of 3󸀠hydroxy-5,6,7,4󸀠-tetramethoxyflavone, sinensetin, and eupatorin,
resp.) showed that it possessed an inhibitory activity against 𝛼-glucosidase in normal rats loaded with starch and sucrose. The
results showed that 1000mg/kg of the 50% ethanolic extract of O. stamineus significantly (𝑃 < 0.05) decreased the plasma glucose
levels of the experimental animals in a manner resembling the effect of acarbose. In streptozotocin-induced diabetic rats, only the
group treatedwith 1000mg/kg of the extract showed significantly (𝑃 < 0.05) lower plasma glucose levels after starch loading.Hence,
𝛼-glucosidase inhibition might be one of the mechanisms by whichO. stamineus extract exerts its antidiabetic effect. Furthermore,
our findings indicated that the 50% ethanolic extract of O. stamineus can be considered as a potential agent for the management of
diabetes mellitus.
1. Introduction
Type 2 diabetes mellitus (DM) is a metabolic disease char-
acterized by hyperglycemia, a condition which could either
be attributed to insufficient insulin secretion or insulin
resistance.The number of diabetic patients is rapidly rising in
most parts of theworld, especially in the developing countries
such as Thailand, India, and Indonesia. Controlling blood
glucose levels of diabetics within the normal range is mainly
based on the use of oral hypoglycemic/antihyperglycemic
agents and insulin. However, these conventional treatments
have undesirable side effects [1–3]. Those shortcomings have
led to a great interest in the use of medicinal plants as alter-
natives for the management of type 2 diabetes mellitus [4].
Control of postprandial plasma glucose levels is critical in the
early treatment of diabetes mellitus and in reducing chronic
vascular complications. Basically, a sudden rise in blood glu-
cose levels, causing hyperglycemia in type 2 diabetic patients,
would be due to starch hydrolysis by the 𝛼-amylase and
𝛼-glucosidases found in gastrointestinal tract [5]. Complex
starches, oligosaccharides, and disaccharides must be broken
down into monosaccharides (glucose and fructose) before
they can be transported across the intestinal lumn (mainly
in duodenum and upper jejunum) into the bloodstream and
thereby increase blood glucose level.Thus, one of the effective
strategies for the management of blood glucose level in type
2 DM is by inhibition of 𝛼-glucosidases and 𝛼-amylase [6,
7] which reduces the digestion of carbohydrates for pro-
duction of monosaccharide and, hence, indirectly decreases
blood glucose level. Among glucose lowering medications,
𝛼-glucosidase inhibitors delay the absorption of ingested
carbohydrates, reducing the postprandial glucose and insulin
peaks [8]. It was demonstrated that 𝛼-glucosidase inhibitors
could be used to prevent disorders such as diabetes, obesity,
hyperlipidaemia, and hyperlipoproteinaemia [9]. Our previ-
ous study showed that 50% ethanolic extract of O. stamineus
and its active ingredient, sinensetin, were able to inhibit 𝛼-
glucosidase and 𝛼-amylase in vitro [10]. To the best of our
knowledge, there have been no other reports on in vivo 𝛼-
glucosidase inhibitory activity of O. stamineus. The present
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 754931, 6 pages
http://dx.doi.org/10.1155/2015/754931
2 Evidence-Based Complementary and Alternative Medicine
study is an extension of our previous work, the objective of
which is to conduct in vivo 𝛼-glucosidase inhibition studies
on experimental animals to further understand the possible
mechanisms of action by which the 50% ethanolic extract of
O. stamineus exerts its antidiabetic effect.
2. Materials and Methods
2.1. Chemicals. Streptozotocin (SigmaAldrich Chemical Co.,
USA), acarbose 50mg (Bayer Pharmaceuticals, Leverkusen,
Germany), starch (Ajax Chemicals, Sydney, Australia),
sucrose and glucose (R & M Chemicals, Essex, UK),
3󸀠hydroxy-5,6,7,4󸀠-tetramethoxyflavone, sinensetin, and
eupatorin (Indofine Chemical Company, New Jersey, USA)
were purchased.
2.2. Plant Material and Extraction. Leaves of Orthosiphon
stamineus were obtained from Kepala Batas, Pulau Pinang,
Malaysia. The plant was identified at the School of Biological
Sciences, Universiti Sains Malaysia, and a voucher specimen
(10810) was deposited at its herbarium. The dried leaves
were powdered using a milling machine and extracted with
50% (v/v) ethanol by maceration (200 g dried leaves in 2 L of
50% ethanol at 55∘C for 24 hours, 2 cycles) over a period of 6
days.The extractwas filtered and concentrated at 40∘Cusing a
rotary evaporator (Buchi Labortechnik, Flawil, Switzerland).
Finally, the concentrated extract was freeze-dried (Labconco
Corporation, Kansas City, MO, USA) to yield a 10.3% of dry
powder.
2.3. HPLC Analysis of the Plant Extract. HPLC analysis was
performed using a Shimadzu-LC system (Shimadzu, Japan)
equipped with a CBM-20A controller, LC-20AT pump,
DGU-20A5 degasser, SIL-20A autosampler, SPD-20AV
detector, and CTO-10ASvp column oven.
Chromatographic separations were achieved using an
Agilent Eclipse Plus C18 (250 × 4.6mm i.d., 5 𝜇m). A Zorbax
guard fittings kit packed with replaceable Eclipse Plus C18
Guard column (12.5 × 4.6mm i.d., 5 𝜇m) was used to protect
the analytical column. A reverse-phase HPLC assay was
carried out using an isocratic system with a flow rate of
1mL/min and a column temperature equaling 25∘C. As the





) (30 : 15 : 55 v/v)was used
with the pH adjusted to 3.5 using 85% phosphoric acid. The
UV detection was set at 340 nm. The injection volume was
20𝜇L. Total run time was less than 20min for each injection
[11]. Data were acquired and processed with LC-Solution
Software. The peaks were detected at 340 nm and identified
using standard substances, namely, sinensetin, eupatorin, and
3󸀠-hydroxy-5,6,7,4󸀠-tetramethoxyflavone. The 50% ethanolic
extract of O. stamineus prepared at 10mg/mL served as the
stock solution. To prepare the sample for injection, the stock
solution was diluted with the mobile phase to a concen-
tration of 1mg/mL. The total amount of 3󸀠hydroxy-5,6,7,4󸀠-
tetramethoxyflavone, sinensetin, and eupatorin in the 50%
ethanol extract of O. stamineus was quantified using a
developed HPLC method (𝑛 = 3). The quantities of these
three compounds were then expressed as percentages of the
dried extract.
2.4. Experimental Animals. Healthy adult male Sprague-
Dawley rats weighing between 200 and 250 g were obtained
from the Animal Research and Service Centre at Universiti
Sains Malaysia (Penang, Malaysia) and housed in the Animal
Transit Room at the School of Pharmaceutical Sciences,
Universiti Sains Malaysia (Penang, Malaysia), five days prior
to the experiment. All the animals used were approved by
the Animal Ethics Committee, Universiti Sains Malaysia,
and maintained in concordance with all international and
national ethical guidelines. The animals had access to food
and water ad libitum. Diabetes was induced in the animals
by a single intraperitoneal injection of 60mg/kg of strepto-
zotocin in ice-cold citrate buffer, pH 4.5. Blood glucose levels
were constantly monitored using an Accu-Chek Advantage-
II Glucose meter (Roche Diagnostics, Manheim, Germany);
and rats showing blood glucose levels approximately 15–
17mmol/L were included in the study. Acarbose was used as
a positive control at a dose of 10mg/kg.
2.5. Oral Carbohydrate Challenge Tests. The oral carbohy-
drate tolerance tests were conducted according to Ye et al.
(2002) [12]. Basically, they were carried out using starch,
sucrose, and glucose in normal and diabetic rats, respectively.
2.5.1. Oral Starch Tolerance Test. Rats were divided into five
groups consisting of six rats each (𝑛 = 6). The rats were
fasted overnight for 12 h but had free access towater.The stan-
dardized 50% ethanol extract of O. stamineus was suspended
in distilled water and administered oral doses of 250mg/kg
(group I), 500mg/kg (group II), and 1000mg/kg (group III).
The control rats (group IV) received the vehicle (distilled
water) only. Treatment (groupV) rats were treated orally with
acarbose at a dose of 10mg/kg. Ten minutes thereafter, all
the rats were loaded with starch orally at a dose of 3 g/kg.
The tails were snipped for blood glucose estimation before
(0min) and at 30, 60, and 120min after starch administration.
2.5.2. Oral Sucrose Tolerance Test. The oral sucrose tolerance
test was carried out similar to Section 2.5.1. However, instead
of starch, the rats were loaded with sucrose at a dose of 4 g/kg.
2.5.3. Oral Glucose Tolerance Test. The oral glucose tolerance
test was carried out similar to Section 2.5.1. However, instead
of starch, the rats were loaded with glucose at a dose of 2 g/kg.
2.6. Statistical Analysis. Data were expressed as mean ±
standard error ofmean (SEM); and the statistical analysis was
performedusing one-way analysis of variance (ANOVA). Sig-
nificant differences between the control and the experimental
groups were determined using the LSD multiple comparison
test. Differences with 𝑃 < 0.05 were considered to be
significant.
3. Results
3.1. Phytochemical Composition. HPLC analysis showed
the percentages of 3󸀠hydroxy-5,6,7,4󸀠-tetramethoxyflavone,
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Figure 1: HPLC chromatogram of standard markers and 50%
ethanolic extract of O. stamineus. Standard compounds: TMF (3󸀠-
hydroxy-5,6,7,4󸀠-tetramethoxyflavone), SEN (sinensetin), and EUP
(eupatorin) (red chromatogram). HPLC chromatogram of 50%
ethanolic extract of O. stamineus (black chromatogram).
sinensetin, and eupatorin in the 50% ethanol extract of O.
stamineus to be 1.02 ± 0.0007, 3.76 ± 0.02, and 3.032 ± 0.03,
respectively (Figure 1).
3.2. Oral Starch Tolerance Test. Using normal rats, extract-
treated groups receiving 250mg/kg and 500mg/kg of the 50%
ethanol extract of O. stamineus did not show any significant
decrease in blood glucose levels (Figure 2(a)) compared to
control rats. Only a dose of 1000mg/kg of the extract reduced
the blood glucose levels significantly (𝑃 < 0.05) after starch
loading. Administered at a dose of 10mg/kg, acarbose also
significantly (𝑃 < 0.05) reduced the blood glucose levels
of starch loaded normal rats. Likewise, using diabetic rats,
only the group treated with 1000mg/kg showed significant
(𝑃 < 0.05) decrease in blood glucose levels following starch
loading (Figure 2(b)). As in the normal rats, 10mg/kg of acar-
bose also significantly (𝑃 < 0.05) decreased the blood glucose
levels of the diabetic rats.
3.3. Oral Sucrose Tolerance Test. In normal rats, 250mg/kg
and 500mg/kg of the 50% ethanol extract of O. stamineus
did not show any reduction in blood glucose levels after
sucrose loading.However, 1000mg/kg of the extractmanaged
to lower the blood glucose levels significantly (𝑃 < 0.05)
compared to the control group (Figure 3(a)). Acarbose given
at a dose of 10mg/kg also produced a significant (𝑃 < 0.05)
blood glucose lowering response in the sucrose-loaded nor-
mal rats. In diabetic rats, none of the extract-treated groups
(250mg/kg, 500mg/kg, and 1000mg/kg) showed any signif-
icant decrease in the blood glucose levels as compared to the
diabetic control group (Figure 3(b)), whereas acarbose pro-
duced a significant (𝑃 < 0.05) blood glucose lowering effect
in the sucrose-loaded STZ-induced diabetic rats.
3.4. Oral Glucose Tolerance Test. In normal rats, none of the
groups treated with the 50% ethanol extract of O. stamineus
showed any significant decreases in the blood glucose levels.
Only acarbose produced a significant (𝑃 < 0.05) blood
glucose lowering effect after glucose loading (Figure 4(a)).
Similarly, using diabetic rats, none of the administered doses
of the extract caused significant reduction in the blood
glucose levels of glucose-loaded STZ-induced diabetic rats
(Figure 4(b)). The acarbose-treated diabetic rats also did not
show any significant reduction in the blood glucose levels.
4. Discussion
Diabetes mellitus is a metabolic disorder of multiple eti-
ologies, characterized by chronic hyperglycemia with dis-
turbances in carbohydrate, fat, and protein metabolism,
resulting from defects in insulin secretion, insulin action, or
both [13]. One therapeutic approach for treating diabetes is to
decrease postprandial hyperglycemia. This is done by delay-
ing the absorption of glucose by inhibiting the carbohydrate
hydrolyzing enzymes, 𝛼-amylase and 𝛼-glucosidase in the
digestive tract. Inhibitors of these enzymes delay carbohy-
drate digestion and prolong its overall digestion time, causing
a reduction in the rate of glucose absorption and conse-
quently blunting the postprandial increase in plasma glucose
[14]. Examples of such inhibitors in clinical use are acarbose,
miglitol, and voglibose [15].The reduction in the postprandial
blood glucose levels caused by 𝛼-glucosidase inhibitors, such
as miglitol and acarbose, following a starch load is well
established.These agents act by inhibiting the last step in car-
bohydrate digestion, namely, the conversion of disaccharides
to monosaccharides (glucose), resulting in a consequent
decrease in the rate of entry of glucose into the systemic
circulation.
Several classes of chemicals have been found inO. stamin-
eus, proving it to be rich in flavonoids, terpenoids, caffeic
acid derivatives, chromene, and phenolic compounds [16–18].
Some of the present phenolic compounds and flavonoids pos-
sess marked antidiabetic activities. Moreover, O. stamineus
aqueous extract has been proven to exert antidiabetic and
lipid lowering effects in diabetic rats [4]. Although there have
been reports on the antihyperglycemic [4] and antidiabetic
[19] activities of O. stamineus aqueous extracts, attributing
their activities to free radical scavenging and, in part, to
increased glucose metabolism, there have been no previous
reports, at least to the best of our knowledge, on the in vivo
activity of this plant extracts in relation to 𝛼-glucosidase and
𝛼-amylase inhibition.
This was the first study to evaluate the in vivo 𝛼-
glucosidase inhibitory effect ofO. stamineus extract in normal
and STZ-induced diabetic rats. In the oral carbohydrate
challenge tests, doses of 250mg/kg and 500mg/kg of a 50%
ethanolic extract ofO. stamineusdidnot reduce blood glucose
levels after oral starch or sucrose loading either in normal
or diabetic rats. The highest dose of 1000mg/kg of the 50%
ethanolic extract ofO. stamineus reduced blood glucose levels
after starch loading in both normal and diabetic rats. How-
ever, upon sucrose loading, the 1000mg/kg dose only caused
a blood glucose lowering response in normal rats but did not
do so in diabetic animals. In the oral glucose tolerance
test, 1000mg/kg of the extract failed to show any significant
blood glucose lowering activity either in normal or diabetic
rats. Nevertheless, the above results for the 1000mg/kg dose
showed a striking similarity to the effects of acarbose. These
findings also agreed with the previous studies in which 50%
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Figure 2: The effect of oral administration of 50% ethanol extract of O. stamineus at doses of 250, 500, and 1000mg/kg on blood glucose
levels of normal rats (a) and diabetic rats (b) loaded with 3 g/kg of starch (a). Values are expressed as mean ± SEM (𝑛 = 6); ∗𝑃 < 0.05 and
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Figure 3:The effect of oral administration of 50% ethanol extract ofO. stamineus at doses of 250, 500, and 1000mg/kg on blood glucose levels
of normal rats (a) and diabetic rats (b) loaded with 4 g/kg of sucrose. Values are expressed as mean ± SEM (𝑛 = 6); ∗𝑃 < 0.05 and ∗𝑃 < 0.01
compared with the control.
ethanolic extract of O. stamineus and the isolated sinensetin
compound showed inhibitory activity on 𝛼-glucosidase and
𝛼-amylase in vitro [10]. Acarbose caused a significant reduc-
tion in blood glucose levels upon starch and sucrose loading
in normal and diabetic rats. In contrast, it failed to inhibit the
increase in the blood glucose levels of glucose-loaded diabetic
rats. 𝛼-Glucosidase inhibitors are competitive inhibitors of
the small intestinal 𝛼-glucosidase enzymes that break down
nonabsorbable oligosaccharides [20]. The most commonly
used 𝛼-glucosidase inhibitor of present so far is acarbose.
Chemically, acarbose is an oligosaccharide produced by
cultured strains of actinomycetes. It is a competitive inhibitor
with a higher affinity for sucrose than glucoamylase and
pancreatic 𝛼-amylase [21]. The 50% ethanolic extract of O.
stamineus seems to delay the rapid digestion of starch and
sucrose, thus, lengthening the time needed for carbohydrate
absorption. It may be that sinensetin or some other unknown
compounds in the extract are responsible for this reduction
in the blood glucose levels of the normal rats. The tendency
of the 50% ethanolic extract of O. stamineus to suppress
the increase in blood glucose levels of starch loaded dia-
betic rats suggests the involvement of 𝛼-glucosidase inhi-
bition. Acarbose-like drugs that inhibit the 𝛼-glucosidases
present in the epithelium of the small intestine, have been
shown to decrease postprandial hyperglycemia [22] and to
improve impaired glucose metabolism without promoting
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Figure 4: The effect of oral administration of 50% ethanol extract of O. stamineus at doses of 250, 500, and 1000mg/kg on blood glucose
levels of normal rats (a) and diabetic rats (b) loaded with 2 g/kg of glucose. Values are expressed as mean ± SEM (𝑛 = 6); ∗𝑃 < 0.05 compared
with the control.
insulin secretion in noninsulin dependent diabetes mellitus
(NIDMM) patients [23]. These medications should be most
useful for people who have just been diagnosed with type
2 diabetes and who have blood glucose levels that are only
slightly above the level considered to be alarming for a dia-
betic. They are also useful for people who take a sulfonylurea
(e.g., glibenclamide) or a biguanide (e.g., metformin) deriva-
tive as a sole medication and who would need additional
medications to keep their blood glucose levels within a safe
range. Therefore, delaying carbohydrate absorption with a
plant-based 𝛼-glucosidase inhibitor such as O. stamineus
extract offers a prospective therapeutic approach for theman-
agement of type 2 diabetes mellitus and may be beneficial for
borderline diabetic patients [24].
Although this extract seems to be promising in the
treatment of type 2 diabetesmellitus by reducing postprandial
hyperglycemia, it is still too early to recommend its use
in human. Only a thorough and full-fledged study could
rationalize its use in human. The results suggest that the 𝛼-
glucosidase inhibitory effect of the 50% ethanolic extract ofO.
stamineusmay contribute to delaying carbohydrate digestion.
Therefore, 𝛼-glucosidase inhibition could possibly be one of
the mechanisms by which the 50% ethanolic extract of O.
stamineus exerts its antidiabetic effects—indicating that O.
stamineus could be considered as a potential drug in the
management of NIDDM. The present results showed that O.
stamineus extract significantly reduced the plasma glucose
concentrations of sucrose-loaded normal and diabetic rats.
Thus,O. stamineus extract may be beneficial for patients with
diabetes mellitus.
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